Volume : 08, Issue : 05, May – 2021
Title:
18.ADVANCES IN THE MANAGEMENT OF DYSLIPIDEMIA
Authors :
Asrar Mohammed Al-Towerqi
Abstract :
Introduction: Dyslipidemia mainly refers to a disbalance of any form of lipid in the body. Any disbalance of lipid in the body puts the body at a higher risk of coronary and peripheral artery diseases. With the discovery of statins, there has been a huge revolution in the treatment of dyslipidemias. They have shown evidence of reduced levels of LDL with statin leading to a reduction in evidence of CVD.
Aim of work: This review aims at discussing the various therapies and new management strategies developed for managing dyslipidemias associated with CVD or Chronic kidney diseases.
Methodology: The review is a comprehensive research of PUBMED, Google Scholar, and WHO official page from the year 2010 to 2021
Conclusion: Dyslipidemias tend to increase the patients’ risk for major cardiovascular events, which can lead to a higher mortality rate in patients with existing cardiac or kidney disorders. There has been an increased interest in the treatment of dyslipidemias, and various genetic therapies and novel medication, including plant-based proteins, have shown a major breakthrough in the management of dyslipidemias. These novel therapies have proven to be a good adjunct to conventional treatment strategies and hence should be tested more thoroughly.
Keywords: Dyslipidemias, Cardiovascular disease, Apolipoproteins, Chronic kidney disease.
Cite This Article:
Please cite this article in press Asrar Mohammed Al-Towerqi., Advances In The Management Of Dyslipidemia.., Indo Am. J. P. Sci, 2021; 08(05).
Number of Downloads : 10
References:
1. Labarthe D R, Goldstein L B, Antman E M, Arnett D K, Fonarow G C, Alberts M J, & Whitsel L P (2016). Evidence-based policy making: assessment of the American Heart Association’s strategic policy portfolio: a policy statement from the American Heart Association. Circulation, 133(18), e615-e653.
2. Omran J, Al-Dadah A, & Dellsperger K C (2013). Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal medicine, 3(3), 165-177.
3. Boekholdt S M, Arsenault B J, Hovingh G K, Mora S, Pedersen T R, LaRosa J C, & Kastelein J J (2013). Levels and changes of HDL cholesterol and apolipoprotein AI in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation, 128(14), 1504-1512.
4. Pulipati V P, & Davidson M H (2020). Recent advances and emerging therapies in management of dyslipidemias. Trends in Cardiovascular Medicine.
5. Nicholls S J, Ray K K, Johansson J O, Gordon A, Sweeney M, Halliday C, & Schwartz G G (2018). Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. American Journal of Cardiovascular Drugs, 18(2), 109-115.
6. Wierzbicki A S, & Viljoen A (2013). Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert opinion on biological therapy, 13(1), 7-10.
7. Mesquita J, Varela A, & Medina J L (2010). Dyslipidemia in renal disease: causes, consequences and treatment. Endocrinología y Nutrición, 57(9), 440-448.
8. Tonelli M A, Wanner C, Upadhyay A, Earley A, Haynes S, Lamont J, & Parekh R S (2013). Kidney disease improving global outcomes KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl, 3, 259-305.
9. Trautwein E A, & McKay S (2020). The role of specific components of a plant-based diet in management of Dyslipidemia and the impact on cardiovascular risk. Nutrients, 12(9), 2671.
10. Feldman F, Koudoufio M, Desjardins Y, Spahis S, Delvin E, & Levy E (2021). Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. Nutrients, 13(2), 672.
11. Keenan J M (2018). The role of niacin in the management of Dyslipidemia. In Dyslipidemia. IntechOpen.
12. Halawani A F M, Alahmari Z S, Asiri D A, Albraheem A A, Alsubaie A M A, Alqurashi A G, & Alghamdi M S S (2019). Diagnosis and Management of Dyslipidemia. Archives of Pharmacy Practice, 10(4).